Ra Capital Management as of March 31, 2023
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 59 positions in its portfolio as reported in the March 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Ascendis Pharma A S (ASND) | 16.9 | $746M | 7.0M | 107.22 | |
| Vaxcyte (PCVX) | 6.2 | $273M | 7.3M | 37.48 | |
| Dice Therapeutics | 5.1 | $225M | 7.9M | 28.65 | |
| 89bio (ETNB) | 3.9 | $174M | 11M | 15.23 | |
| Aerovate Therapeutics (AVTE) | 3.8 | $167M | 8.3M | 20.17 | |
| Biogen Idec (BIIB) | 3.4 | $148M | 533k | 278.03 | |
| Verona Pharma Plc ads (VRNA) | 2.9 | $127M | 6.3M | 20.08 | |
| Cytek Biosciences Sponsored Adr (CTKB) | 2.8 | $123M | 13M | 9.19 | |
| Vor Biopharma (VOR) | 2.8 | $122M | 23M | 5.38 | |
| Legend Biotech 2 Adr Rep Ord (LEGN) | 2.7 | $118M | 2.4M | 48.22 | |
| Tyra Biosciences (TYRA) | 2.6 | $116M | 7.2M | 16.07 | |
| Janux Therapeutics (JANX) | 2.4 | $105M | 8.7M | 12.10 | |
| Pepgen (PEPG) | 2.3 | $100M | 8.1M | 12.23 | |
| Avidity Biosciences Ord (RNA) | 2.2 | $99M | 6.4M | 15.35 | |
| Rhythm Pharmaceuticals (RYTM) | 2.2 | $98M | 5.5M | 17.84 | |
| Day One Biopharmaceuticals I (DAWN) | 2.1 | $94M | 7.0M | 13.37 | |
| Bellus Health | 2.1 | $91M | 13M | 7.20 | |
| Curevac N V Sponsored Ads (CVAC) | 1.9 | $85M | 12M | 6.97 | |
| Immunogen Class A Com | 1.9 | $84M | 22M | 3.84 | |
| Wave Life Sciences (WVE) | 1.7 | $75M | 17M | 4.33 | |
| Inhibrx (INBX) | 1.6 | $73M | 3.9M | 18.87 | |
| Geron Corp Ads (GERN) | 1.5 | $69M | 32M | 2.17 | |
| Cogent Biosciences (COGT) | 1.5 | $65M | 6.0M | 10.79 | |
| Celldex Therapeutics (CLDX) | 1.4 | $62M | 1.7M | 35.98 | |
| Acrivon Therapeutics (ACRV) | 1.4 | $61M | 4.8M | 12.69 | |
| Iteos Therapeutics Sponsored Adr (ITOS) | 1.4 | $60M | 4.4M | 13.61 | |
| Newamsterdam Pharma Co Nv (NAMS) | 1.2 | $53M | 4.0M | 13.26 | |
| Miragen Therapeutics (VRDN) | 1.2 | $51M | 2.0M | 25.44 | |
| Rxsight Ordinary Shares (RXST) | 1.2 | $51M | 3.1M | 16.68 | |
| Mineralys Therapeutics (MLYS) | 1.1 | $50M | 3.2M | 15.66 | |
| Pliant Therapeutics (PLRX) | 1.1 | $47M | 1.8M | 26.60 | |
| Enliven Therapeutics (ELVN) | 1.1 | $47M | 2.1M | 21.90 | |
| Gh Research (GHRS) | 1.0 | $45M | 5.6M | 7.99 | |
| Acumen Pharmaceuticals Sponsored Ads (ABOS) | 0.9 | $40M | 9.8M | 4.06 | |
| Eliem Therapeutics (ELYM) | 0.9 | $38M | 13M | 2.90 | |
| An2 Therapeutics (ANTX) | 0.8 | $37M | 3.8M | 9.87 | |
| Alpine Immune Sciences Common Stock (ALPN) | 0.8 | $36M | 4.7M | 7.72 | |
| Aclaris Therapeutics (ACRS) | 0.8 | $36M | 4.4M | 8.09 | |
| Icosavax | 0.8 | $35M | 6.0M | 5.80 | |
| Fulcrum Therapeutics (FULC) | 0.7 | $33M | 12M | 2.85 | |
| Hillevax (HLVX) | 0.7 | $29M | 1.8M | 16.53 | |
| Nkarta (NKTX) | 0.6 | $28M | 7.8M | 3.55 | |
| Kinnate Biopharma (KNTE) | 0.6 | $27M | 4.3M | 6.25 | |
| Nanostring Technologies SHS (NSTGQ) | 0.6 | $24M | 2.5M | 9.90 | |
| Silverback Therapeutics (SPRY) | 0.4 | $20M | 3.0M | 6.51 | |
| Rocket Pharmaceuticals (RCKT) | 0.4 | $19M | 1.1M | 17.13 | |
| Tenaya Therapeutics (TNYA) | 0.4 | $17M | 6.1M | 2.85 | |
| Design Therapeutics (DSGN) | 0.4 | $17M | 3.0M | 5.77 | |
| Solid Biosciences (SLDB) | 0.4 | $16M | 3.4M | 4.74 | |
| Werewolf Therapeutics (HOWL) | 0.4 | $16M | 6.1M | 2.60 | |
| Celcuity (CELC) | 0.3 | $14M | 1.4M | 10.25 | |
| Eyepoint Pharmaceuticals (EYPT) | 0.2 | $9.9M | 3.4M | 2.94 | |
| Connect Biopharma Hldgs Class A Ord Shs (CNTB) | 0.2 | $7.0M | 7.0M | 1.00 | |
| Black Diamond Therapeutics (BDTX) | 0.1 | $4.9M | 2.6M | 1.89 | |
| Aadi Bioscience (AADI) | 0.1 | $4.3M | 590k | 7.24 | |
| Satsuma Pharmaceuticals Ord Shs | 0.1 | $4.1M | 5.9M | 0.70 | |
| Fusion Pharmaceuticals (FUSN) | 0.1 | $2.5M | 660k | 3.77 | |
| Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.0 | $613k | 333k | 1.84 | |
| Entera Bio (ENTX) | 0.0 | $343k | 296k | 1.16 |
